Ariad Pharmaceuticals (NASDAQ: ARIA) gained approval from the Food and Drug Administration for its chronic myeloid leukemia drug Iclusig in mid-December. The drug is currently approved for patients who don't respond to treatment with Novartis' (NVS -0.12%) Gleevec, Tasigna, or Bristol-Myers Squibb's (BMY -0.18%) Sprycel. With FDA approval now complete, the big question mark hanging over Ariad in 2013 is whether its Iclusig launch will be successful. In this video, analyst Max Macaluso weighs in and highlights issues that investors need to watch this year.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.